Tocilizumab for treating juvenile idiopathic arthritis.

Item

http://www.wikidata.org/entity/Q38723988

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Tocilizumab for treating juvenile idiopathic arthritis.

@en

type

Item

label

Tocilizumab for treating juvenile idiopathic arthritis.

@en

prefLabel

Tocilizumab for treating juvenile idiopathic arthritis.

@en

P1476

Tocilizumab for treating juvenile idiopathic arthritis.

@en

P2093

Hermine I Brunner

http://www.w3.org/2001/XMLSchema#string

Jessica L Turnier

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolong

A comparative proteomic study of sera in paediatric systemic lupus erythematosus patients and in healthy controls using MALDI-TOF-TOF and LC MS-A pilot study.

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.

The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis.

Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.

Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.

P304

559-566

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2016.1150997

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26848760

http://www.w3.org/2001/XMLSchema#string

P921

juvenile rheumatoid arthritis

Tocilizumab for treating juvenile idiopathic arthritis.

about

P2860

P2860

Tocilizumab for treating juvenile idiopathic arthritis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921